Comparison
Abacavir Hypersensitivity C5768819 vs 3mc Syndrome 2 C0796279
Clinical comparison between Abacavir Hypersensitivity and 3mc Syndrome 2 for differential diagnosis and treatment planning.
Abacavir Hypersensitivity C5768819
A potentially serious immune reaction to the HIV drug abacavir. Genetic testing is required before starting treatment to identify those at risk of this reaction.
3mc Syndrome 2 C0796279
A rare genetic condition similar to other 3MC types, affecting multiple systems with facial, developmental, and growth manifestations. Treatment focuses on symptom management.
6 comparison axes
Onset
Abacavir Hypersensitivity C5768819
Variable
3mc Syndrome 2 C0796279
0-0
Onset patterns differ
Severity
Abacavir Hypersensitivity C5768819
severe
3mc Syndrome 2 C0796279
moderate
Different severity levels
Chronic
Abacavir Hypersensitivity C5768819
Acute
3mc Syndrome 2 C0796279
Chronic
Differing course
Communicable
Abacavir Hypersensitivity C5768819
No
3mc Syndrome 2 C0796279
No
Different transmission
Body System
Abacavir Hypersensitivity C5768819
immunologic
3mc Syndrome 2 C0796279
congenital
Same/different system
Category
Abacavir Hypersensitivity C5768819
immunologic
3mc Syndrome 2 C0796279
genetic
Different category
Bottom line
abacavir-hypersensitivity-C5768819 and 3mc-syndrome-2-C0796279 differ in severity, chronicity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | Abacavir Hypersensitivity C5768819 | 3mc Syndrome 2 C0796279 | Discriminating power |
|---|---|---|---|
| Timing of onset | Usually appears after abacavir exposure; timing varies. | Present from birth or early development. | High |
| System pattern | Acute multisystem immune symptoms after drug exposure. | Congenital facial, growth, and developmental features. | High |
| Course | Acute and potentially severe if exposure continues. | Chronic, generally moderate, lifelong condition. | Moderate |
When to favor each condition
Choose Abacavir Hypersensitivity C5768819 when
New symptoms after starting abacavir
Drug timing strongly supports a hypersensitivity reaction.
High
Positive HLA-B*5701 risk marker
This marker identifies higher risk before treatment.
High
Symptoms improve after supervised drug withdrawal
Resolution after stopping supports a drug reaction.
Moderate
Choose 3mc Syndrome 2 C0796279 when
Congenital facial and growth findings
Early structural features fit a genetic syndrome.
High
No relevant drug exposure
Absence of abacavir makes hypersensitivity unlikely.
High
Family or genetic evaluation suggests 3MC
Specialist genetic confirmation is needed.
Moderate
How key tests differ
| Test | Abacavir Hypersensitivity C5768819 | 3mc Syndrome 2 C0796279 | Interpretation |
|---|---|---|---|
| HLA-B*5701 testing | Used before abacavir to identify risk. | Not diagnostic for 3MC syndrome 2. | A risk marker, not proof of an active reaction. |
| Syndrome-directed genetic testing | Not used to diagnose drug hypersensitivity. | May support a 3MC diagnosis when clinically indicated. | Interpretation requires genetics expertise. |
| Clinical exposure history | Recent abacavir use is central. | Findings are independent of drug exposure. | History often separates the conditions. |
Prognosis comparison
Abacavir Hypersensitivity C5768819
- Outcome
- May improve after abacavir is stopped, but severe reactions can occur.
- Factors
- Early recognition, avoidance of re-exposure, and clinical severity.
3mc Syndrome 2 C0796279
- Outcome
- Chronic condition managed supportively; exact outlook is not established here.
- Factors
- Specific genetic findings, affected systems, and available supportive care.
Time frame: Hours to weeks for drug reaction; lifelong for the syndrome.
Cause, exposure history, severity, and access to specialist care.
Complications comparison
| Complication | Presentation |
|---|---|
| Acute deterioration | Can become severe with continued exposure. Not typically an acute drug-triggered illness. Urgent clinician review is needed for suspected hypersensitivity. |
| Developmental effects | Not a congenital developmental disorder. May involve developmental and growth concerns. Support needs vary and are not fully established here. |
| Recurrence risk | Re-exposure may be dangerous. Course reflects an inherited condition, not rechallenge. Do not restart abacavir without specialist advice. |
Patient education highlights
- HighDrug warning
Report fever, rash, or systemic symptoms during abacavir promptly and do not restart it independently.
- MediumDifferent conditions
A drug reaction and a congenital syndrome require different evaluation and care.
- MediumSpecialist follow-up
HIV, allergy, genetics, or pediatric specialists should guide testing and management.